Article

Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion.

Department of Surgical Oncology and Regulation of Organ Function, Miyazaki University School of Medicine, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan.
Journal of Gastrointestinal Surgery (impact factor: 2.83). 12/2008; 13(3):492-7. DOI:10.1007/s11605-008-0751-0 pp.492-7
Source: PubMed

ABSTRACT To clarify the characteristics of hepatocellular carcinoma (HCC) with bile duct invasion, we retrospectively analyzed clinical features and surgical outcome of HCC with bile duct invasion (b(+) group, n = 15) compared to those without bile duct invasion (b(-) group, n = 256). In the b(+) group, four patients (27%) showed obstructive jaundice, and a diagnosis of bile duct invasion was obtained preoperatively in seven patients (47%). The levels of serum bilirubin and carbohydrate antigen 19-9 were significantly higher in the b(+) group. Macroscopically, confluent multinodular type and infiltrative type were predominant in the b(+) group (P = 0.002). Microscopically, capsule infiltration (P = 0.040) and intrahepatic metastasis (P = 0.013) were predominant in the b(+) group. Portal vein invasion was associated significantly with the b(+) group (P = 0.004); however, the frequency of hepatic vein invasion was similar (P = 0.096). The median survival after resection was significantly shorter in the b(+) group than in the b(-) group (11.4 vs. 56.1 months, P = 0.002), and eight of 11 intrahepatic recurrences in the b(+) group occurred within 3 months after surgery. HCC with bile duct invasion has an infiltrative nature and a high risk of intrahepatic recurrence, resulting in poor prognosis.

0 0
 · 
0 Bookmarks
 · 
48 Views
  • Source
    Article: Surgical outcome of hepatocellular carcinoma patients with biliary tumor thrombi.
    Wenyu Shao, Chengjun Sui, Zhenyu Liu, Jiamei Yang, Yanming Zhou
    [show abstract] [hide abstract]
    ABSTRACT: To investigate the surgical outcome of hepatocellular carcinoma (HCC) patients with biliary tumor thrombi (BTT). Surgical outcome of 27 HCC patients with BTT (group I) were compared with randomly selected HCC patients without BTT (group II; n = 270). One patient in group I died of hepatic failure within 30 days after resection. The 1-, 3- and 5-year cumulative survival rates of group I were 70.3%, 25.9%, and 7.4%, respectively; these were significantly lower than those of group II (90.6%, 54.0%, and 37.7%) (P <0.001). The rates of early recurrence (≤ 1 year) after resection were significantly higher in group I than group II (70.3% vs. 34.8%) (P < 0.001). HCC patients with BTT had a worse prognosis after resection than those without BTT. Resection should be considered for these tumors given the lack of effective alternative therapies.
    World Journal of Surgical Oncology 01/2011; 9:2. · 1.12 Impact Factor
  • Source
    Article: Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection.
    Yoji Kishi, Kiyoshi Hasegawa, Yasuhiko Sugawara, Norihiro Kokudo
    [show abstract] [hide abstract]
    ABSTRACT: Currently, surgical resection is the treatment strategy offering the best long-term outcomes in patients with hepatocellular carcinoma (HCC). Especially for advanced HCC, surgical resection is the only strategy that is potentially curative, and the indications for surgical resection have expanded concomitantly with the technical advances in hepatectomy. A major problem is the high recurrence rate even after curative resection, especially in the remnant liver. Although repeat hepatectomy may prolong survival, the suitability may be limited due to multiple tumor recurrence or background liver cirrhosis. Multimodality approaches combining other local ablation or systemic therapy may help improve the prognosis. On the other hand, minimally invasive, or laparoscopic, hepatectomy has become popular over the last decade. Although the short-term safety and feasibility has been established, the long-term outcomes have not yet been adequately evaluated. Liver transplantation for HCC is also a possible option. Given the current situation of donor shortage, however, other local treatments should be considered as the first choice as long as liver function is maintained. Non-transplant treatment as a bridge to transplantation also helps in decreasing the risk of tumor progression or death during the waiting period. The optimal timing for transplantation after HCC recurrence remains to be investigated.
    International journal of hepatology. 01/2011; 2011:728103.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

11 intrahepatic recurrences
 
3 months
 
bile duct invasion
 
capsule infiltration
 
characteristics
 
clarify
 
hepatic vein invasion
 
hepatocellular carcinoma
 
infiltrative nature
 
intrahepatic metastasis
 
intrahepatic recurrence
 
Macroscopically
 
median survival
 
obstructive jaundice
 
Portal vein invasion
 
resection
 
serum bilirubin
 

Naoki Ikenaga